Tivicay set to become leading HIV treatment by 2016

15 January 2014

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment of HIV by 2016, according to independent analyst firm Datamonitor Healthcare.

Tivicay is marketed by ViiV Healthcare, the HIV/AIDS joint venture set up by GlaxoSmithKline (LSE: GSK) with Pfizer (NYSE: PFE) and Shionogi (TYO: 4507). In November it was approved in Canada after being approved by the US Food and Drug Administration in the summer. Datamonitor analysts say it is expected to generate annual sales of up to $2.1 billion by 2022 in the USA, Japan and five major EU markets of France, Germany, Italy, Spain and the UK, equating to 12.6% of the total combined value of these markets.

Better efficacy than Prezista or Isentress

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK